Preclinical
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs
Summit Therapeutics plc announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves.
Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
According to a University College London (UCL) report, British researchers are being shut out of major European research partnerships because of concerns over a no-deal Brexit.
Orion Biotechnology Canada Ltd. announced the publication of preclinical data evaluating the efficacy of OB-002 in a murine model of multiple sclerosis in Science Translation Medicine
Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system.
PRESS RELEASES